Blog - Page 410 of 5636 - QualityStocks

WednesdayJul 24, 2024 12:21 pm

QualityStocksNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Receives PO from European Distributor for 29 Mullen GOs

Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, has received an order for 29 Mullen GOS from one of its newest European distribution partners. The order for the GOs, which are Mullen’s commercial micro-urban-delivery vehicle, came from GAMA, which is a distribution partner covering southeast Europe, including the Balkans Region. The order from GAMA, which is valued at $304,000, is part of a previously announced 53-unit commercial vehicle order; that order is for urban delivery vehicles as well as Mullen One and Mullen Three commercial EV cargo vans and trucks, which have not yet been delivered. The compact design…

WednesdayJul 24, 2024 11:43 am

QualityStocksNewsBreaks – Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF), American West Metals Release Update for Storm Project Drilling, Exploration

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF), a publicly traded mineral exploration company exploring for high-grade copper and gold deposits in Virginia and Nunavut, Canada, along with its joint venture partner American West Metals Limited, is reporting on the status of drilling and exploration activities currently underway at the Storm Copper Project. The project is located on Somerset Island, Nunavut, and is being conducted by American West Metals Limited, which has formed a 20/80 unincorporated joint venture with Aston Bay on the project. Highlights of the update indicate that the excellent productivity for the 2024 summer drilling program is…

WednesdayJul 24, 2024 11:23 am

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives US Patent for Methods of Treating Acute Traumatic Brain Injury with Its Lead Drug Candidate

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent covers methods of treating acute traumatic brain injuries (“TBI”) and preventing nerve cell death with its lead drug candidate, buntanetap. Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This improves synaptic transmission, axonal transport, and reduces neuroinflammation. “We are thrilled to achieve this significant milestone for buntanetap,” said Maria Maccecchini, Ph.D., Founder,…

WednesdayJul 24, 2024 9:45 am

SenesTech Inc.’s (NASDAQ: SNES) Evolve(TM) – Offering Sustainable and Humane Solution to NYC’s Rat Problem

New York City has received lots of backlash, mainly from People for the Ethical Treatment of Animals (“PETA”), for its approach to addressing its rat problem Its approach, so far, has been characterized by the use of traps, poisons, and its “Trash Revolution” program, all of which have been unsustainable SenesTech, a rodent fertility control product provider, through its flagship Evolve(TM) product, offers an alternative that could potentially eliminate the entire rodent population in 12 to 18 months This solution avoids the adverse effects of the use of poisons, both to humans and other animals, and offers a sustainable, more…

WednesdayJul 24, 2024 9:00 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a high unmet medical need Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality of life, making it…

TuesdayJul 23, 2024 10:41 am

QualityStocksNewsBreaks – Mullen Automotive Inc.’s (NASDAQ: MULN) Subsidiary Announces Warranty Coverage for B4 Chassis Cab

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has announced that its subsidiary, Bollinger Motors, released its full warranty coverage on the Bollinger B4 Chassis Cab, the company’s all-new, all-electric Class 4 commercial truck. “We have designed and engineered the Bollinger B4 to have unmatched capability and durability, and we are proud to be offering warranty coverage to reflect that,” said Jim Connelly, chief revenue officer of Bollinger Motors. “Our warranty provides our customers the peace of mind they need in making their decision and demonstrates the confidence we have in the B4.” To view the full press…

TuesdayJul 23, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members

The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), is thrilled to welcome four seasoned professionals to its executive team. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, said the company was delighted to have this strong group of individuals join…

TuesdayJul 23, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at Emerging Growth Conference 73 – Biotech Feature

CNM-Au8(R) works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health Clene has conducted several clinical trials to evaluate the safety and efficacy of CNM-Au8 in neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) The global ALS treatment market is expected to grow significantly, driven by the increasing prevalence of the disease among the aging population Clene has submitted a briefing book to the FDA to seek feedback on a potential pathway for accelerated approval for CNM-Au8 to treat ALS Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative…

MondayJul 22, 2024 1:20 pm

QualityStocksNewsBreaks – Meta Platforms Inc. (NASDAQ: META) Expands Business Model in India with Meta Verified

Meta Platforms (NASDAQ: META), a leading tech giant known for its social media platforms such as Facebook, Instagram, and WhatsApp, is taking significant steps to expand its business model. By introducing Meta Verified for businesses in India, the company aims to enhance the social commerce ecosystem, providing tools like a verified badge, enhanced account support, and protection against impersonation. This initiative is particularly timely, as social media plays an increasingly pivotal role in retail, especially among younger consumers who frequently discover and purchase products through these platforms. The decision to broaden its business subscription program to include Indian users underscores…

MondayJul 22, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing

Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2 The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug For Lexaria, the results from this study look to validate earlier studies that have demonstrated improvements in the delivery of semaglutide into the bloodstream Results from the GLP-1-H24-2 study are set to be announced in late August or early September Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the dosing completion of its human pilot study #2, GLP-1-H24-2.…

Site Search

Company Search